CEL-SCI (CVM) Competitors $0.40 +0.00 (+0.90%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends CVM vs. XBIT, ATOS, LPTX, IVA, ANRO, NVCT, TARA, INZY, MGX, and IGMSShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include XBiotech (XBIT), Atossa Therapeutics (ATOS), Leap Therapeutics (LPTX), Inventiva (IVA), Alto Neuroscience (ANRO), Nuvectis Pharma (NVCT), Protara Therapeutics (TARA), Inozyme Pharma (INZY), Metagenomi (MGX), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. XBiotech Atossa Therapeutics Leap Therapeutics Inventiva Alto Neuroscience Nuvectis Pharma Protara Therapeutics Inozyme Pharma Metagenomi IGM Biosciences CEL-SCI (NYSE:CVM) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment. Does the media refer more to CVM or XBIT? In the previous week, CEL-SCI and CEL-SCI both had 2 articles in the media. CEL-SCI's average media sentiment score of 0.49 beat XBiotech's score of 0.00 indicating that CEL-SCI is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CEL-SCI 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral XBiotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in CVM or XBIT? XBiotech received 317 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 69.98% of users gave XBiotech an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote. CompanyUnderperformOutperformCEL-SCIOutperform VotesNo VotesUnderperform Votes12100.00% XBiotechOutperform Votes31769.98% Underperform Votes13630.02% Which has more volatility & risk, CVM or XBIT? CEL-SCI has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Is CVM or XBIT more profitable? XBiotech's return on equity of -15.99% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -228.43% -100.46% XBiotech N/A -15.99%-14.85% Which has better earnings and valuation, CVM or XBIT? XBiotech has higher revenue and earnings than CEL-SCI. XBiotech is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$26.92M-$0.51-0.79XBiotech$4.01M29.04-$24.56M-$1.08-3.54 Do insiders and institutionals hold more shares of CVM or XBIT? 12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 14.1% of CEL-SCI shares are owned by company insiders. Comparatively, 33.1% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryXBiotech beats CEL-SCI on 9 of the 11 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$29.83M$2.96B$5.34B$19.90BDividend YieldN/A1.90%5.37%3.63%P/E RatioN/A18.0457.4634.24Price / SalesN/A287.691,272.2217.10Price / CashN/A192.9536.6620.32Price / Book2.013.964.885.78Net Income-$26.92M-$41.02M$118.05M$1.00B7 Day Performance-0.57%1.13%1.45%2.23%1 Month Performance-44.84%-1.72%2.50%4.72%1 Year Performance-83.43%-2.23%25.79%18.80% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCIN/A$0.40+0.9%N/A-83.4%$29.83MN/A0.0043Gap UpXBITXBiotech0.6227 of 5 stars$3.85-0.8%N/A-17.8%$117.36M$4.01M-3.56100ATOSAtossa Therapeutics1.364 of 5 stars$0.92+1.8%$7.00+661.0%+0.7%$115.72MN/A-4.188LPTXLeap Therapeutics1.9237 of 5 stars$3.02-1.3%$7.50+148.3%-20.1%$115.72M$1.50M-1.5640Gap DownIVAInventiva2.6351 of 5 stars$2.19+0.9%$13.25+505.0%-43.6%$114.93M$15.62M0.00100Positive NewsANROAlto Neuroscience2.5969 of 5 stars$4.24-2.5%$20.00+371.7%N/A$114.35M$210,000.000.00N/AGap DownNVCTNuvectis Pharma2.9906 of 5 stars$5.87+1.0%$21.00+257.8%-33.0%$113.41MN/A-5.068Positive NewsTARAProtara Therapeutics2.541 of 5 stars$5.24-5.8%$22.67+332.6%+138.2%$108.10MN/A-1.8630INZYInozyme Pharma3.4605 of 5 stars$1.68-16.0%$18.33+991.3%-68.4%$107.92MN/A-1.0850Short Interest ↑Gap UpMGXMetagenomi1.6562 of 5 stars$2.88-8.0%$16.67+478.7%N/A$107.78M$55.08M0.00236Positive NewsGap DownIGMSIGM Biosciences4.6968 of 5 stars$1.81-13.4%$5.50+203.9%-83.2%$107.63M$2.92M-0.50190Gap Up Related Companies and Tools Related Companies XBiotech Competitors Atossa Therapeutics Competitors Leap Therapeutics Competitors Inventiva Competitors Alto Neuroscience Competitors Nuvectis Pharma Competitors Protara Therapeutics Competitors Inozyme Pharma Competitors Metagenomi Competitors IGM Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CVM) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
